



[Frontiers In Bioscience, Landmark, 23, 967-996, January 1, 2018]

Leishmaniasis treatment: update of possibilities for drug repurposing

Valter Viana Andrade-Neto¹, Edezio Ferreira Cunha-Junior¹, Viviane dos Santos Faioes¹, Thais Pereira Martins¹, Raphaela Lopes Silva¹, Leonor Laura Leon¹, [Eduardo Caio Torres-Santos¹](#)

¹Laboratorio de Bioquimica de Tripanosomatideos, Instituto Oswaldo Cruz, Fiocruz, Rio de Janeiro, Brasil

TABLES

Table 1. Species pathogenic to human, occurrence and clinical manifestation

Complex	Species	Ocurrence	Clinical manifestation
Viannia	<i>L. shawi</i>	NW ¹ / OW ²	CL ³
	<i>L. peruviana</i>	NW ¹	CL ³ , MCL ⁴
	<i>L. panamensis</i>	NW ¹	CL ³ , MCL ⁴
	<i>L. lindenbergi</i>	NW ¹	CL ³
	<i>L. naiffi</i>	NW ¹	CL ³
	<i>L. braziliensis</i>	NW ¹	CL ³ , MCL ⁴
	<i>L. guyanensis</i>	NW ¹	CL ³ , MCL ⁴
	<i>L. lainsoni</i>	NW ¹	CL ³
Leishmania	<i>L. venezuelensis</i>	NW ¹	CL ³
	<i>L. tropica</i>	OW ²	CL ³ , VL ⁵
	<i>L. mexicana</i>	NW ¹	CL ³ , DCL ⁶
	<i>L. major</i>	OW ²	CL ³
	<i>L. infantum</i>	NW ¹ / OW ²	VL ⁵ , CL ³
	<i>L. donovani</i>	OW ²	VL ⁵ , PKDL ⁷
	<i>L. amazonensis</i>	NW ¹	CL ³ , DCL ⁶ , MCL ⁴ , VL
	<i>L. aethiopica</i>	OW ²	CL ³ , DCL ⁶
Enrietti	<i>L. martiniquensis</i>	NW ¹ / OW ²	CL ³ , VL ⁵
	<i>L. siamensis</i>	NW ¹ / OW ²	VL ⁵ , CL ³
Paraleishmania	<i>L. colombiensis</i>	NW ¹	CL ³ , VL ⁵

¹New World, ²Old World, ³Cutaneous leishmaniasis, ⁴Mucocutaneous leishmaniasis, ⁵Visceral leishmaniasis, ⁶Difuse cutaneous leishmaniasis, ⁷Post-kala-azar dermal leishmaniasis

Abstract

Fulltext

Figures

Tables

PDF



Copyright ©
Frontiers in
Bioscience,
2018